Shots: Moderna amended its current supply agreement with the UK govt. for an additional 2M doses of mRNA-1273 against COVID-19. The UK govt. has now secured 7M doses of mRNA-1273 […]readmore
Tags : Amends
Shots: Chi-Med to receive 70%-80% of Elunate sales in the form of royalties, manufacturing costs and service payments with no upfront regarding this amendment. Lilly will maintain the exclusive commercialization […]readmore
Shots: Under the amended agreement, the offer price increased from $44.5 to $49/QIAGEN share in cash, representing a premium of 35% to the closing price of QIAGEN’s ordinary shares on […]readmore
Shots: Aurigene to fund and conduct P-IIb/III study assessing CA-170 + chemoradiation in ~240 patients with nsq. NSCLC and get exclusive rights to develop and commercialize CA-170 in Asia in […]readmore
Shots: Editas to receive $70M up front, milestone and royalty payments for each therapy developed by Celgene and will develop genome editing tool for which Celgene has right to opt-in […]readmore
Shots: As per the amended agreement, Gilead will reduce the royalty rates of Momelotinib & eliminates milestone payments in exchange for becoming a stockholder in Sierra, following the closing of […]readmore
Shots: Ironwood to receive three non-contingent payment of $35M b/w 2021 & 2024, ~$90M as a milestone with royalties on sales of Linzess in China mainland, China Hong Kong and […]readmore
Shots: GSK to get rights to develop and commercialize three additional inhaled therapies utilizing Liquidia’s PRINT technology and can acquire rights to pursue additional PRINT based inhalation therapies. Liquidia to […]readmore
Shots: The amendments accelerate timelines for the anticipated primary completion dates of both trials ARCHES and EMBARK Phase III trials have been amended its primary completion time from April 2020 […]readmore